Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Why Opendoor Technologies Stock Popped Today (Fool) +++ OPENDOOR Aktie -3,33%

ME THERAPEUTICS Aktie

>ME THERAPEUTICS Performance
1 Woche: 0%
1 Monat: 0%
3 Monate: +18,0%
6 Monate: +143,8%
1 Jahr: +137,9%
laufendes Jahr: +128,7%
>ME THERAPEUTICS Aktie
Name:  ME THERAPEUTICS H
Land:  Kanada
Sektor:  Gesundheit
ISIN/ Wkn:  CA5527671054 / A3ECDH
Symbol/ Ticker:  Q9T (Frankfurt)
Kürzel:  FRA:Q9T, ETR:Q9T, Q9T:GR
Index:  -
Webseite:  https://www.metherapeutic..
Marktkapitalisierung:  170.83 Mio. EUR
Umsatz:  -
EBITDA:  -1.19 Mio. EUR
Gewinn je Aktie:  -0.026 EUR
Schulden:  0.09 Mio. EUR
Liquide Mittel:  1.74 Mio. EUR
Umsatz-/ Gewinnwachstum:  - / -
KGV/ KGV lG:  - / -
KUV/ KBV/ PEG:  - / 109.79 / -
Gewinnm./ Eigenkapitalr.:  - / -73.59%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  ME THERAPEUTICS, ME THERAPEUTIC
Letzte Datenerhebung:  16.07.25
>Eigentümer
Aktien: 26.19 Mio. St.
f.h. Aktien: 9.35 Mio. St.
Insider Eigner: 55.31%
Instit. Eigner: -
Leerverk. Aktien: -
>Peer Group

1CM
 
21.05.25 - 12:06
 ME Therapeutics Receives Support to Advance mRNA Therapeutic Candidates for Cancer and Inflammatory Disease (Business Wire)
 
VANCOUVER, British Columbia--(BUSINESS WIRE)--ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed preclinical biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, today announced that its subsidiary, ME Therapeutics Inc., is receiving advisory services and up to $140,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The project will support the research and development of ME Therapeutic's mRNA therapeutic program targeting myeloid cell biology for the treatment of cancer and inflammatory disease. “We are pleased to receive this support from NRC IRAP, which builds on advisory services and funding received in past years, to allow us to further advance preclinical studies for our mRNA therapeutic candidates that target key myeloid cell pathways,” said Salim Dhanji, CEO of ME Therapeutics. “Our team at ME Therapeutics passionately believe...
03.03.25 - 15:06
 ME Therapeutics Holdings Inc.: ME Therapeutics Announces It Has Engaged Lucosky Brookman LLP to Explore a Listing on the NASDAQ or NYSE (Newsfile)
 
Vancouver, British Columbia--(Newsfile Corp. - March 3, 2025) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company......
14.01.25 - 15:42
 ME Therapeutics Holdings Inc.: ME Therapeutics Announces That Its First Therapeutic mRNA Candidate Shows Encouraging Anti-Cancer Efficacy in Vivo (Newsfile)
 
Vancouver, British Columbia--(Newsfile Corp. - January 14, 2025) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology comp......
25.10.24 - 15:13
 ME Therapeutics Holdings Inc. Appoints Chief Business Officer (Newsfile)
 
Vancouver, British Columbia--(Newsfile Corp. - October 25, 2024) - ME Therapeutics Holdings Inc. (CSE:METX) (FSE:Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology compan......
22.10.24 - 12:06
 ME Therapeutics Holdings Inc. Provides Research and Development Update and Corporate Update (Newsfile)
 
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology comp......
18.09.24 - 15:07
 ME Therapeutics Holdings Inc.: ME Therapeutics Announces the Start of Testing of First mRNA Formulations from NanoVation Therapeutics Collaboration (Newsfile)
 
Vancouver, British Columbia--(Newsfile Corp. - September 18, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology co......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Malern und Dichtern war es stets gleichermaßen erlaubt zu sagen, was auch immer ihnen beliebt. - Quintus Flaccus Horaz
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!